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NASAL DOSAGE FORMS CONTAINING 
NATURAL FEMALE SEX HORMONES 
This application is a continuation, of application Ser. 
No.l54,995, ?led May 30, 1980 now US. Pat. No. 
‘ 4,315,925. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to a novel method of 
administering the natural female sex hormones, 17 B 
estradiol and progesterone, and to novel dosage forms 
containing those compounds, singly or in combination, 
which are adapted for nasal administration. 
2. Description of the Prior Art 
17 B-estradiol is the most potent natural estrogen 
found in human beings and is the major secretory prod 
uct of the ovary. It is readily oxidized in the body to 
estrone, which in turn can be hydrated to estriol. These 
transformations take place mainly in the liver, where 
there is free interconversion between estrone and estra 
diol. All three of these natural estrogens are excreted in 
the urine as glucuronides and sulfates, along with a host 
of related, minor products in water-soluble complexes. 
It is widely known that, following oral administration 
of micronized l7 B-estradiol (E2), the incremental cir 
culation estrogen is principally the less active species 
estrone (E1), which reaches a peak concentration many 
times greater than that of E2. The conversion of E1 to 
E1 and subsequently to other metabolites takes place 
during absorption from the intestine and passage 
through the liver. This extensive metabolism greatly 
limits the oral effectiveness of the natural estrogens and 
their esters. Indeed, because of their limited oral effl 
cacy, l7 B-estradiol and its esters are generally adminis 
tered by intramuscular injection. 
Progesterone is the active natural progestin which 
occurs in the corpus luteum, placenta and adrenal cor 
tex. It is not effective by mouth because of its rapid 
metabolism in the intestinal epithelium and in the liver, 
and is therefore only administered intramuscularly. 
Because of their limited oral effectiveness, these natu 
ral female sex hormones have not found utility in oral 
contraceptives. Instead, only active synthetic estrogens 
and progestins have been prepared and are used for 
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contraceptive purposes. The synthetic derivatives have ‘ 
also in many cases replaced the natural substances in the 
treatment of menopause, threatened abortion, etc. How 
ever, the synthetic derivatives are, generally speaking, 
much more likely to cause toxic side effects than are the 
relatively safe natural hormones. 
SUMMARY OF THE INVENTION 
In view of the foregoing, it is apparent that a serious 
need exists for the improved delivery of the natural 
female sex hormones. Thus, it is an object of the present 
invention to provide novel dosage forms and a novel 
method of administering l7 B-estradiol and progester 
one, separately or in combination, which will provide 
greatly enhanced bioavailability as compared to oral 
administration, while at the same time providing rela 
tive ease of administration when compared to intramus 
cular injection. 
It is a further object of the present invention to pro 
vide a novel contraceptive method and novel composi 
tions for accomplishing same which utilize the natural 
female sex hormones, l7 B-estradiol and progesterone, 
65 
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and thus avoid the disadvantages inherent in the use of 
potentially unsafe synthetic estrogens and progestins. 
It is yet a further object of the present invention to 
provide a novel method and novel dosage forms con 
taining 17 B-estradiol or progesterone useful in the 
treatment of conditions such as menopause, menstrual 
disorders, etc. which are known to respond to adminis 
tration of a natural or synthetic female sex hormone. 
The foregoing objects are achieved by nasal adminis 
tration of l7 B-estradiol (if desired, in the form of one of 
its estrogenically effective esters) and/or progesterone. 
According to the invention, these natural female sex 
hormones are administered via a novel nasal dosage 
form, i.e., a solution, suspension, ointment or gel 
adapted for nasal administration. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a semi-logarithmic plot of mean blood levels 
of progesterone after intravenous (IV), nasal and in 
traduodenal/oral (ID) administration of a dose of 50 pg 
of progesterone per rat. 
FIG. 2 is a graph showing the area under the curve as 
a function of dose for the intravenous (IV) and nasal 
routes of progesterone administration (50 pg, 100 pg 
and 150 pg dosage levels). 
FIG. 3 is a semi-logarithmic plot of mean blood levels 
of total unconjugated estrogens (TUE) following intra 
venous (IV), nasal and intraduodenal/oral (ID) admin 
istration of a dose of 10 pg of 17 B-estradiol per rat. 
FIG. 4 is a semi-logarithmic plot of mean blood levels 
of estradiol (E2) following intravenous (IV), nasal and 
intraduodenal/oral (ID) administration of a dose of 10 
pg of l7 B-estradiol per rat. a 
FIG. 5 is a semi-logarithmic plot of mean blood levels 
of estrone (E1) following intravenous (IV), nasal and 
intraduodenal/oral (ID) amdinistration of a dose of 10 
pg of 17 B-estradiol per rat. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The word “progesterone" as used herein means 
pregn-4-ene-3,20-dione, i.e., the compound of the for 
mula 
0% 
and is intended to include progesterone derived from 
natural sources as well as that made synthetically. 
The word “17 B-estradiol” as used herein is intended 
to encompass any pharmaceutically acceptable, estro 
genically active form of 17 B-estradiol, i.e., estra 
l,3,5(l0)-triene-3,17 B-diol itself, which has the formula 
4,383,993 
HO 
and which may be extracted from natural sources or 
made synthetically, or one of its 3- or l7-monoesters or 
3,17-diesters. By way of illustration, suitable esters of 17 
B-estradiol for purposes of the present invention include 
3-monoesters such as estradiol benzoate and estradiol 
3-acetate; l7-monoesters such as estradiol cypionate, 
estradiol l7-propionate, estradiol l7-acetate, estradiol 
l7-heptan0ate (estradiol enanthate), estradiol 17 
undecanoate (estradiol undecylate) and estradiol l7-val 
erate; and 3,17-diesters such as estradiol dipropionate 
and estradiol diacetate. 
According to the present invention, it has surpris 
ingly been found that 17 B-estradiol and progesterone 
can be administered nasally with results considerably 
superior to those obtained with oral administration. The 
following studies were undertaken to examine the bi 
oavailability of progesterone and 17 B-estradiol from 
nasal solution in comparison with the bioavailability of 
these drugs when administered orally and intrave 
nously. 
Sprague-Dawley male rats, each weighing about 270 
grams, were used in the progesterone study. For nasal 
administration, the rats were anesthetized using sodium 
pentobarbital (50 mg/kg) and the drug was adminis 
tered to the nasal cavity by means of a micropipet at 
dosage levels of 50 pg, 100 pg and 150 pg/‘rat of [4 
14C]-progesterone (~8.5 pCi/rat) in 0.1 ml of isotonic 
saline containing l—2% Tween 80 as a solubilizing 
agent, according to the procedure described by Hirai et 
al, the 98th Annual Meeting of Pharmaceutical Society 
of Japan, Okayama, April 1978, eitcept that the end of 
the tube leading from the esophagus to the nasal cavity 
was closed and the drug was administered to the nostrils 
which were then closed with an adhesive agent. For 
oral (intraduodenal) administration, the rats were anes 
thetized and the abdomen of each rat was opened 
through a rnidline incision and a 50 pg/rat dose of the 
drug ([4-l4C]-progesterone in 0.1 ml isotonic saline with 
l-2% Tween 80) was injected directly through the 
duodenum. For intravenous administration, the rats 
were anesthetized and the drug was injected through 
the femoral vein at dosage levels of 50 pg, 100 pg and 
150 pg/ rat of [4~l4C]-progesterone in 0.1 ml of isotonic 
saline containing l—2% Tween 80. Blood was sampled 
periodically from the femoral aorta after IV and nasal 
administration, and from the tail vein after ID adminis 
tration. Blood levels of progesterone were determined 
by thin layer chromotography. 
FIG. 1 shows the mean blood levels of progesterone 
for the study described above after intravenous, nasal 
and oral administration of a dose of 50 pg/rat, while 
Table I below summarizes the area under the curve for 
the three routes of administration at the various doses. 
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TABLE I 
AREA UNDER THE CURVE AFTER INTRAVENOUS, 
NASAL AND INTRADUODENAL ADMINISTRATION 
OF PROGESTERONE IN RATS 
Dose AUQQ, ng. min/ml Nasal ID 
pg/rat IV Nasal ID IV IV 
50 1612.2‘ 1659.0 19.0 1.029 0.012 
t 80.8 i 109.2 i 4.6 
100 3520.0 3599.0 — 1.022 -— 
i 491.0 : 621.4 
150 4480.2 4798.9 - 1.07] -— 
1 466.4 1 188.5 
‘mean : SE(n = 4-6).“ 
By using the two tailed t-test, it can be shown that the 
area under the curve following intravenous and nasal 
administration at each dose were not signi?cantly dif 
ferent, even at the 0.001 level. However, as can be seen 
from Table I, oral administration of 50 pg resulted in 
bioavailability equal to only 1.2% that of an equivalent 
dose given intravenously. Also from Table I, it can be 
seen that the nasal bioavailability of progesterone at the 
50 pg dosage level was 85.75 times greater than the oral 
bioavailability. 
It can also be seen from FIG. 1 that progesterone is 
very rapidly absorbed from the nasal mucosa; thus, at 
thei50 pg dosage level, the peak plasma level was at~ 
tained in less than 7 minutes after instillation of the nose 
drops. 
FIG. 2 shows the area under the curve as a function 
of dose for the intravenous and nasal routes. As can be 
seen from FIG. 2, for both IV and nasal routes of ad 
ministration the area under the curve (AUC) was di 
rectly proportional to the dose administered. 
The study described above indicates that progester 
one is rapidly absorbed from the nasal mucosa into the 
systemic circulation without ?rst pass metabolism. It is 
further apparent from this study that the bioavailability 
of progesterone when administered nasally is equivalent 
to the bioavailability of the drug where administered 
intravenously and vastly superior to its bioavailability 
by the oral route. ’ 
A study similar to that described above was under— 
taken to study the bioavailability of nasally adminis 
tered l7 B-estradiol vis-a-vis its bioavailability via intra 
venous and oral routes. Sprague-Dawley male rats, 
each weighing approximately 270 grams, were given 
dosages of 5 pg, 10 pg and 20 pg/rat of [6,7-3I-I] l7 
B-estradiol in 0.1 ml isotonic saline containing 1% 
Tween 80 via the intravenous, nasal and intraduodenal 
routes, according to the procedures described above 
with respect to the progesterone study. Blood samples 
were taken periodically as described in the progester 
one study and assayed for estradiol (E2), estrone (E1) 
and total unconjugated estrogens (TUE). 
FIGS. 3, 4 and“ 5 show typical plots of the mean blood 
levels of TUE, E2 and E1 following intravenous, nasal 
and oral administration of 10 pg of 17 B-estradiol per 
rat. These ?gures clearly show that 17. B-estradiol is 
rapidly absorbed by the nasal mucosa. 
Table II below shows the area under the curve for the 
three routes of administration at the various dosage 
levels of 17 B-estradiol. 
4,383,993 
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TABLE 11 
AREA UNDER THE CURVE AND BIOAVAILABILITY 
OF TUE, E; AND E) FOR THE DIFFERENT ROUTES 
OF ADMINISTRATION AT THE VARIOUS DOSES 
DOSE ROUTE 0F Augq.No.M1N.ML—1 5 
)tG/RAT ADMINISTRATION TUE E; E( 
5 IV 555.5 2903 53.4 
NASAL 331.0 146.8 88.5 
(0.606) (0.505) (1.657) 
ORAL 119.2 11.1 10.6 (0 
(0.215) (0.038) (0.199) 
10 iv 954.6 609.0 83.5 
NASA]. 761.2 415.2 173.1 
(0.791) (0.682) (2.013) 
ORAL 314.2 19.1 l6.8 
(0.329) (0.031) (0.201) 15 
20 iv 1936.9 1062.6 l64.4 
NASAL 1777.2 891.8 354.0 
(0.9115) (0.339) (2.153) 
ORAL 786.9 53.4 42.4 
(0.406) (0.050) (0.255) 
( ) RATIO VS. IV 
As can be seen from Table II, the TUE bioavailability 
after nasal administration ranged from 60.6% to 91.8% 
that of the correspondng doses given intravenously, 
while oral administration resulted in TUE bioavailabil 
ity that ranged from only 21.5% to 40.6% that of the 
corresponding doses given intravenously. Thus, nasal 
bioavailability of TUE was from 2.26 to 2.83 times 
greater than oral bioavailability. Even more signi? 
cantly, Table [I further shows that the E; bioavailability 
after nasal administration ranged from 50.5% to 83.9% 
that of the corresponding doses given intravenously, 
while oral administration resulted in E2 bioavailabilities 
that ranged from only 3.1% to 5.0% that of the corre 
sponding doses given intravenously. Thus, nasal bi 
oavailability of E2 was from l3.23 to 21.74 times greater 
than oral bioavailability. 
The studies described above indicate that progester 
one 17 B-estradiol are rapidly absorbed from the nasal 
mucosa into systemic blood without extensive intestinal 
or ?rst pass metabolism. 
Progesterone and I7 B-estradiol can be conveniently 
administered nasally to warm-blooded animals by for 
mulating them, singly or in combination, into a nasal 
dosage form comprising the selected natural female sex 
hormone(s) and a nontoxic pharmaceutically acceptable 
nasal carrier therefor. As indicated earlier, any pharma 
ceutically acceptable, estrogenically active form of 17 
B-estradiol can be employed in the nasal form, e.g., the 
diol itself or one of its esters. In a preferred embodiment 
of the invention, both progesterone and a suitable form 
of 17 B-estradiol are present in the nasal dosage form, 
which can be employed in preventing conception, for 
example, by administration in a cyclic manner anala 
gous to that used for the oral contraceptives. 
In another embodiment, the estrogenic component, 
i.e., one of the suitable forms of 17 Bestradiol, is present 
but progesterone is not; this type of composition may be 
used for any of a variety of conditions for which natural 
or synthetic estrogens have previously been adminis 
tered, e.g., to control menopausal symptoms, hot ?ushes 
and later osteoporosis; also in atropic vaginitis, and to 
relieve postpartum breast en gorgement, dysmenorrhea, 
amenorrhea, memorrhagia, and as substitution therapy 
in ovarian dwarfism; also to control prostatic carci 
noma, and possibly also as a “morning-after” contracep 
tive. Also, the “estrogen only” nasal composition could 
be used in a sequential contraceptive regimen in which 
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estrogen alone is to be administered for a part of th 
cycle. ‘ 
In another embodiment of the present invention, pro 
gesterone is present in the nasal dosage form, but the 
estrogenic component is not. This type of composition 
may be used in the treatment of conditions for which 
natural or syntheic progestins have previously been 
used, tag, in threatened or habitual abortion, endometri 
osis and menstrual disorders such as dysmenorrhea and 
functional uterine bleeding, in inhibiting ovulation and 
possibly as a “progestin only" continuously adminis 
tered contraceptive (analogous to “minipill" type of 
oral contraceptives). 
Suitable nontoxic pharmaceutically acceptable nasal 
carriers for use in the compositions of the present inven 
tion will be apparent to those skilled in the art of nasal 
pharmaceutical formulations. For those not skilled in 
the art, reference is made to the text entitled “REM 
INGTON‘S PHARMACEUTICAL SCIENCES", 4th 
edition, 1970. Obviously, the choice of suitable carriers 
will depend on the exact nature of the particular nasal 
dosage form desired, e.g. whether the active in 
gredient(s) is/are to be formulated into a nasal solution 
(for use as drops or as a spray), a nasal suspension, a 
nasal ointment or a nasal gel, as well as on the identity 
of the active ingredient(s). Preferred nasal dosage forms 
are solutions, suspensions and gels, which contain a 
major amount of water (preferably puri?ed water) in 
addition to the active ingredient(s). Minor amounts of 
other ingredients such as pH adjusters (e.g., a base such 
as NaOH), emulsi?ers or dispersing agents (cg. poly 
oxyethylene 20 sorbitan mono-oleate), buffering agents, 
preservatives, wetting agents and jelling agents (e.g. 
methylcellulose) may also be present. Also, a sustained 
release composition, e.g. sustained release gel, readily 
can be prepared by employing l7 B-estradiol in one of 
its relatively insoluble, long-acting forms, e.g. as estra 
diol cypionate. 
Examples of the preparation of typical nasal composi 
tions are not set forth below. However, it is to be under 
stood that these examples are given by way of illustra 
tion only and are not to be construed as limiting the 
invention either in spirit or in scope as many modi?ca 
tions both in materials and in methods will be apparent 
to those skilled in the art. 
EXAMPLE I 
25 milligrams of progesterone and 5 milligrams of 17 
?-estradiol were combined with 10 milligrams of 
Tween 80. That mixture was then combined with a 
quantity of isotonic saline sufficient to bring the total 
volume to 50 milliliters. The solution was sterilized by 
being passed through a 0.2 micron Millipore ?lter. 
EXAMPLE 2 
50 milligrams of progesterone and 5 milligrams of 17 
B-estradiol were combined with 10 milligrams of 
Tween 80. That mixture was then combined with a 
quantity of isotonic saline sufficient to bring the total 
volume of the solution to 50 milliliters. The solution was 
sterilized by being passed through a 0.2 micron Mil 
lipore filter. 
EXAMPLE 3 
250 milliliters of isotonic saline were heated to 80° C. 
and 1.50 grams of Methocel were added, with stirring. 
The resultant mixture was allowed to stand at room 
temperature for 2 hours. Then, 50 milligrams of proges 
4,383,993 
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terone and 10 milligrams of 17 B-estradiol were mixed 
together with 10 milligrams of Tween 80. The steroid/ 
Tween mixture and a quantity of isotonic saline suffi 
cient to bring the total volume to 500 milliliters were 
added to the gel and thoroughly mixed. 
EXAMPLE 4 
Repetition of the procedure of Example 1, but omit 
ting the 25 milligrams of progesterone, affords an “es 
trogen only” nasal composition. 
EXAMPLE 5 
Repetition of the procedure of Example 2, but omit 
ting the 5 milligrams of l7B-estradiol, affords a “proges 
terone only " nasal composition. 
EXAMPLE 6 
Substitution of an equivalent quantity of estradiol 
benzoate, estradiol cypionate, estradiol dipropionate, 
estradiol enanthate or estradiol l7-valerate for the 173 
estradiol employed in Example 1, 2, 3 or 4 and repeti 
tion of the procedures there detailed affords other nasal 
compositions according to the invention. 
Naturally, the therapeutic dosage range for nasal 
administration of the compositions of the present inven 
tion will vary with the size of the patient, the condition 
for which the composition is administered and the par~ 
ticular form of l7B-estradiol employed (when the com 
position is an “estrogen only” or estrogen/progestin 
combination). A typical dose of a combination form for 
use as a contraceptive would be from 10 pg to 500 pg of 
l7B-estradiol and from 10 pg to 5000 pg of progester 
one, administered nasally once daily. The quantity of 
nasal dosage form needed to deliver the desired dose 
will of course depend on the concentration of the active 
ingredients in the composition. For example, when a 
composition as described in Example 2 above is used to 
deliver a typical dose of 0.5 mg of progesterone, the 
volume of solution which would be needed would be 
approximately 0.5 ml. 
While the invention has been described in terms of 
various preferred embodiments, the skilled artisan will 
appreciate that various modi?cations, substitutions, 
omissions and additions may be made without departing 
from the spirit thereof. Accordingly, it is intended that 
the scope of the present invention be limited solely by 
the scope of the following claims. 
What is claimed is: 
1. A pharmaceutically acceptable nasal composition, 
in dosage unit form, for nasal administration to a female 
mammal for the purpose of mammalian contraception, 
said composition consisting essentially of, per nasal unit, 
a systemically effective contraceptive amount of a com 
bination of progesterone and a pharmaceutically ac 
ceptable, estrogenically active form of l7B-estradiol, 
together with a nontoxic pharmaceutically acceptable 
nasal carrier therefor, said composition comprising a 
nasal ointment or a nasal gel. 
2. A composition according to claim 1, wherein the 
pharmaceutically acceptable, estrogenically active form 
of l7B-estradiol is selected from the group consisting of 
l7B~estradiol, 3-monoesters of l7B-estradiol, l7-mono 
esters of l7B-estradiol and 3,17-diesters of 173 
estradiol. 
3. A composition according to claim 2, wherein the 
pharmaceutically acceptable, estrogenically active form 
of l7B-estradiol is l7B-estradiol. 
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4. A composition according to claim 2, wherein the 
pharmaceutically acceptable, estrogenically active form 
of l7B-estradiol is estradiol benzoate. 
5. A composition according to claim 2 wherein the 
pharmaceutically acceptable, estrogenically active form 
of 17B-estradiol is estradiol cypionate. 
6. A composition according to claim 2, wherein the 
pharmaceutically acceptable, estrogenically active form 
of 17,6-estradiol is estradiol dipropionate. 
7. A composition according to claim 2, wherein the 
pharmaceutically acceptable, estrogenically active form 
of l7B-estradiol is estradiol enanthate. 
8. A composition according to claim 2, wherein the 
pharmaceutically acceptable, estrogenically active form 
of l7B-estradiol is estradiol l7-valerate. 
9. A composition according to claim 1, said composi 
tion comprising a nasal ointment. 
10. A composition according to claim 1, said compo 
sition comprising a nasal gel. 
11. A composition according to claim 10, said compo 
sition comprising a sustained release nasal gel. 
12. A composition according to claim 1, containing 
from about 10 pg to 5000 pg of progesterone and from 
about 10 pg to 500 pg of a pharmaceutically acceptable, 
estrogenically active form of l7B-estradiol. 
13. A pharmaceutically acceptable nasal composition, 
in dosage unit form, for nasal administration to elicit a 
systemic progestational response in a mammal, said 
composition consisting essentially of, per nasal dosage 
unit, a systemically therapeutically effective progesta 
tional amount of progesterone and a nontoxic pharma 
ceutically acceptable nasal carrier therefor, said compo 
sition comprising a nasal ointment or a nasal‘gel. 
14. A composition according to claim 13, said compo 
sition comprising a nasal ointment. 
15. A composition according to claim 13, said compo 
sition comprising a nasal gel. 
16. A pharmaceutically acceptable nasal composition, 
in dosage unit form, for nasal administration to elicit a 
systemic estrogenic response in a mammal, said compo 
sition consisting essentially of, per nasal dosage unit, a 
systemically therapeutically effective estrogenic 
amount of a pharmaceutically acceptable, estrogeni 
cally active form of l7B-estradiol and a nontoxic phar 
maceutically acceptable nasal carrier therefor, said 
composition comprising a nasal ointment or a nasal gel. 
17. A composition according to claim 16, wherein the 
pharmaceutically acceptable, estrogenically active form 
of l7B-estradiol is selected from the group consisting of 
l7B-estradiol, 3-monoesters of l7B-estradiol, l7-mono 
esters of l7B-estradiol and 3,17-diesters of l7B- estra 
diol. 
18. A composition according to claim 17, wherein the 
pharmaceutically acceptable, estrogenically active form 
of l7B-estradiol is l7B-estradiol. 
19. A composition according to claim 17, wherein the 
pharmaceutically acceptable, estrogenically active form 
of l7B-estradiol is estradiol benzoate. 
20. A composition according to claim 17, wherein the 
pharmaceutically acceptable, estrogenically active form 
of 17B-estradiol is estradiol cypionate. 
21. A composition according to claim 17, wherein the 
pharmaceutically acceptable, estrogenically active form 
of Hit-estradiol is estradiol dipropionate. 
22. A composition according to claim 17, wherein the 
pharmaceutically acceptable, estrogenically active form 
of l7B-estradiol is estradiol enanthate. 
4,383,993 
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23. A composition according to claim 17, wherein the 25. A composition according to claim 16, said compo 
pharmaceutically acceptable, estrogenically active form sition comprising a nasal gel. 
of l7B-estradiol is estradiol l7-valerate. 26. A composition according to claim 25, said compo 
24. A composition according to claim 16, said compo- sition comprising a sustained release nasal gel. 
sition comprising a nasal ointment. 5 ' " "‘ ‘ * 
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